Navigation Links
Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
Date:8/24/2009

HOERSHOLM, Denmark, August 24 /PRNewswire/ --

- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders

- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery

- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance.

Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of US$6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of US$13.5 million upon successful completio
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
4. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Pre-Owned Prices on Premium Pharmaceutical Equipment
9. Laureate Pharma Elects New Board Member
10. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
11. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... LAS VEGAS, Dec. 16 Cord Blood ... cord blood stem cell preservation company ( http://www.cordblood-america.com ... potential of stem cells, a biological insurance policy, ... it has reduced its debt by a total ... quarter of 2009 and total debt eliminated for ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader in the ... of the cutting-edge science behind its lead oncology ... world rediscovered the Cyclin G1 gene ... and disease progression, and thus a prime target ... National Cancer Institute investigating the role of microRNAs ...
(Date:12/15/2009)... Aethlon Medical, Inc. (OTC Bulletin Board : AEMD) ... Wayne Comper have joined the Science ... Dr. Schorey and Dr. Comper are leading researchers ... subsidiary of Aethlon Medical, was recently formed to ... device being advanced as an adjunct therapy for ...
Breaking Biology Technology:Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5
... VAP(R) Cholesterol Test helps physicians identify emerging risk factors ... study showsBIRMINGHAM, Ala., Jan. 30 Traditional ... blood pressure do a poor job of predicting heart ... history of early heart disease. That,s according to a ...
... Journal Indicates Masimo SET May Also Reduce the Need for ... Jan. 30 Masimo (Nasdaq: ... Motion and Low Perfusion pulse oximetry, today announced that a ... January 2009 issue of the British Medical Journal ...
... a leader in adult stem cell production, announced today the appointment ... will be responsible for developing pre-clinical and clinical trial protocols for ... products. , ... San Diego, CA (PRWEB) January 30, ...
Other Biology Technology:Traditional Risk Factors Often Miss Heart Disease Warning Signs 2Traditional Risk Factors Often Miss Heart Disease Warning Signs 3Traditional Risk Factors Often Miss Heart Disease Warning Signs 4New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 2New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 3New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 4New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 5Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 2Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 3
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin Board: BKYI), ... today announced that SC Magazine, one of ... BIO-key International the 2009 Innovator of the ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) ,, ... Magazine, "Biometric providers have been trying for ...
(Date:12/15/2009)... 2009 Frost & Sullivan European Border Security ... Securite (Safran Group) for its innovative Automated ... company,s expertise in advanced biometric technology and ... products to end users. ,, (Logo: ... has been involved in delivering identification systems ...
(Date:12/15/2009)... has just signed an agreement with the British Society ... affiliation with the journal Biogerontology for an ... appoint one member of the Biogerontology editorial ... annually. Springer will sponsor the society and provide ... on www.springerlink.com . , Biogerontology ...
Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Grupo Casa Saba Announces 3Q09 Earnings Report 5804 1Grupo Casa Saba Announces 3Q09 Earnings Report 5804 2Grupo Casa Saba Announces 3Q09 Earnings Report 5804 3Grupo Casa Saba Announces 3Q09 Earnings Report 5804 4Grupo Casa Saba Announces 3Q09 Earnings Report 5804 5Experience the Future of Assistive Technology at Abilities Expo on November 6 8 2009 60288 1Experience the Future of Assistive Technology at Abilities Expo on November 6 8 2009 60288 2Legislation in India to Address Assisted Reproductive Technology Egg Donation and Surrogacy 60286 1Legislation in India to Address Assisted Reproductive Technology Egg Donation and Surrogacy 60286 2
... orange cauliflower may seem unappealing to some, it has ... genetic mutation behind the unusual hue. The finding may ... rice, sorghum and wheat. , The genetic mutation ... colleagues -- and described in the December issue of ...
... on a train, HIV, the virus that causes AIDS, ... cell and infect new ones, Hopkins scientists have discovered. ... Biology, counter the prevailing belief that HIV and other ... mechanisms. , “It appears that cells make HIV ...
... battle to save Australia’s iconic Tasmanian devils from the ... CSIRO’s Livestock Industries’ Australian Animal Health Laboratory (AAHL), Textiles ... together to hunt down the cause of Devil Facial ... identify infected animals. , DFTD is infectious ...
Other Biology News:Discovery in orange cauliflower may lead to more nutritious crops 2How sneaky HIV escapes cells 2CSIRO scientists join fight to save 'Tassie devil' 2
... Microarrays designed for immunological studies, ... on the flexible and powerful Paraflo ... are available as part of our ... Custom Probe Content Probe ...
... of Molecular Imaging (MI) Software for use ... research and drug discovery applications. The Regulatory ... and Drug Administrations Code of Federal Regulations ... Signatures [21 CFR Part 11]. KODAK MI ...
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
Biology Products: